Bicycle Therapeutics plc: Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle Tumor-targeted Immune Cell Agonist BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
BT7480 is the Company's Fourth Product Candidate to Enter the Clinic in the Past Four Years This is Bicycle's First Immuno-oncology Asset to Enter the Clinic Bicycle Therapeutics plc (NASDAQ: BCYC)
Source: finanznachrichten.de